Literature DB >> 26062595

Post hoc subgroups in clinical trials: Anathema or analytics?

Herbert I Weisberg1, Victor P Pontes2.   

Abstract

BACKGROUND: There is currently much interest in generating more individualized estimates of treatment effects. However, traditional statistical methods are not well suited to this task. Post hoc subgroup analyses of clinical trials are fraught with methodological problems. We suggest that the alternative research paradigm of predictive analytics, widely used in many business contexts, can be adapted to help.
METHODS: We compare the statistical and analytics perspectives and suggest that predictive modeling should often replace subgroup analysis. We then introduce a new approach, cadit modeling, that can be useful to identify and test individualized causal effects.
RESULTS: The cadit technique is particularly useful in the context of selecting from among a large number of potential predictors. We describe a new variable-selection algorithm that has been applied in conjunction with cadit. The cadit approach is illustrated through a reanalysis of data from the Randomized Aldactone Evaluation Study trial, which studied the efficacy of spironolactone in heart-failure patients. The trial was successful, but a serious adverse effect (hyperkalemia) was subsequently discovered. Our reanalysis suggests that it may be possible to predict the degree of hyperkalemia based on a logistic model and to identify a subgroup in which the effect is negligible.
CONCLUSION: Cadit modeling is a promising alternative to subgroup analyses. Cadit regression is relatively straightforward to implement, generates results that are easy to present and explain, and can mesh straightforwardly with many variable-selection algorithms.
© The Author(s) 2015.

Entities:  

Keywords:  Highly Accurate and Robust Variable Evaluation Selection and Testing; Randomized Aldactone Evaluation Study; Subgroups; adaptive signature; cadit; personalized medicine; precision medicine; predictive analytics; spironolactone

Mesh:

Substances:

Year:  2015        PMID: 26062595     DOI: 10.1177/1740774515588096

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  6 in total

1.  Recursive partitioning for heterogeneous causal effects.

Authors:  Susan Athey; Guido Imbens
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-05       Impact factor: 11.205

2.  Evaluating Markers for Guiding Treatment.

Authors:  Stuart G Baker; Marco Bonetti
Journal:  J Natl Cancer Inst       Date:  2016-05-18       Impact factor: 13.506

3.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.

Authors:  David M Kent; David van Klaveren; Jessica K Paulus; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

4.  Automated interpretable discovery of heterogeneous treatment effectiveness: A COVID-19 case study.

Authors:  Benjamin J Lengerich; Mark E Nunnally; Yin Aphinyanaphongs; Caleb Ellington; Rich Caruana
Journal:  J Biomed Inform       Date:  2022-04-30       Impact factor: 8.000

5.  Individualized treatment effects with censored data via fully nonparametric Bayesian accelerated failure time models.

Authors:  Nicholas C Henderson; Thomas A Louis; Gary L Rosner; Ravi Varadhan
Journal:  Biostatistics       Date:  2020-01-01       Impact factor: 5.899

Review 6.  Predictive approaches to heterogeneous treatment effects: a scoping review.

Authors:  Alexandros Rekkas; Jessica K Paulus; Gowri Raman; John B Wong; Ewout W Steyerberg; Peter R Rijnbeek; David M Kent; David van Klaveren
Journal:  BMC Med Res Methodol       Date:  2020-10-23       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.